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Abstract
Background: Malaria transmission in Ethiopia is unstable and variable, caused by both Plasmodium falciparum and
Plasmodium vivax. The Federal Ministry of Health (FMoH) is scaling up parasitological diagnosis of malaria at all
levels of the health system; at peripheral health facilities this will be through use of rapid diagnostic tests (RDTs).
The present study compared three RDT products to provide the FMoH with evidence to guide appropriate product
selection.
Methods: Performance of three multi-species (pf-HRP2/pan-pLDH and pf-HRP2/aldolase) RDTs (CareStart®,
ParaScreen® and ICT Combo®) was compared with ‘gold standard’ microscopy at three health centres in Jimma
zone, Oromia Regional State. Ease of RDT use by health extension workers was assessed at community health
posts. RDT heat stability was tested in a controlled laboratory setting according to WHO procedures.
Results: A total of 2,383 patients with suspected malaria were enrolled between May and July 2009, 23.2% of
whom were found to be infected with Plasmodium parasites by microscopy. All three RDTs were equally sensitive
in detecting P. falciparum or mixed infection: 85.6% (95% confidence interval 81.2-89.4). RDT specificity was similar
for detection of P. falciparum or mixed infection at around 92%. For detecting P. vivax infection, all three RDTs had
similar sensitivity in the range of 82.5 to 85.0%. CareStart had higher specificity in detecting P. vivax (97.2%) than
both ParaScreen and ICT Combo (p < 0.001 and p = 0.05, respectively). Health extension workers preferred
CareStart and ParaScreen to ICT Combo due to the clear labelling of bands on the cassette, while the ‘lab in a
pack’ style of CareStart was the preferred design. ParaScreen and CareStart passed all heat stability testing, while
ICT Combo did not perform as well.
Conclusions: CareStart appeared to be the most appropriate option for use at health posts in Ethiopia, considering
the combination of quantitative performance, ease of use and heat stability. When new products become available,
the choice of multi-species RDT for Ethiopia should be regularly re-evaluated, as it would be desirable to identify a
test with higher sensitivity than the ones evaluated here.
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Approximately 52 million people in Ethiopia are consid-
ered to be at risk of malaria [1]. The disease is report-
edly the leading cause of morbidity, accounting for
about 12% of the total outpatient visits and 9.9% of the
total admissions in 2007 [2]. Between 4-6 million clini-
cal malaria cases are reported annually across all health
facilities in the country, however the actual number of
malaria cases is estimated to be as high as 10-15 million
[3]. The major Plasmodium species causing malaria in
Ethiopia are Plasmodium falciparum and Plasmodium
vivax, for which the national guidelines prescribe treat-
ment with the artemisinin combination therapy (ACT)
artemether-lumefantrine (CoArtem®) or with chloro-
quine, respectively; Plasmodium ovale and Plasmodium
malariae are rare. To reduce costs and minimise selec-
tion for drug resistance in Plasmodium parasites there is
considerable pressure to minimise ACT use. This can
only be achieved once parasitological diagnosis of
malaria is routinely provided at all levels of the health
system. Parasitological diagn o s i si sp a r t i c u l a r l yi m p o r -
tant in low transmission settings where a large propor-
tion of febrile illness is due to causes other than malaria.
Rapid diagnostic tests (RDTs) for detection of P. falci-
parum (ParaCheck-Pf®, Orchid Biomedical Systems,
Goa, India) have been used by health extension workers
(HEWs) at health posts in Ethiopia since 2005 [3-7].
(Description of Ethiopian health system in Additional
file 1). Currently, there is no capacity for parasitological
diagnosis of non-falciparum malaria at health facilities
without laboratory services. RDTs using Plasmodium
lactate dehydrogenase (pLDH) to detect non-falciparum
malaria were initially less reliable than histidine-rich
protein 2 (HRP2)-based tests [8-11]. However, recent
studies have shown sensitivity and specificity of pLDH-
based RDTs approaching those of falciparum-only tests
[12-15], to the extent where they may be appropriate for
routine use in case management at facilities where
microscopy is not available.
The present study was conducted to determine the
performance of three multi-species RDTs for diagnosis
of P. falciparum and P. vivax malaria in Ethiopia. The
aim of this study was to establish which multi-species
RDTs can be recommended for routine use at health
posts in Ethiopia.
Methods
Study setting
The study was conducted from April to August 2009 in
three woredas; Omo Nada, Kersa and Tiro Afeta; in the
Jimma zone of Oromia Regional State, Ethiopia (Figure
1). Within each woreda, one health centre and three
health posts were purposively selected according to
reported malaria cases. Jimma zone is 300 km south-
west of Addis Ababa, and has an elevation of approxi-
mately 1,780 meters above sea level. Malaria transmis-
sion in Oromia is perennial, but peaks from April to
May and from October to December, after the seasonal
rains.
Rapid Diagnostic Tests
Three RDT products were compared: i) CareStart®
pf-HRP2/pan-pLDH (AccessBio, USA, catalogue number
G0131SK), ii) ParaScreen® pf-HRP2/pan-pLDH (Zephyr
Biomedicals, India, catalogue number 50310025), and iii)
ICT Combo® pf-HRP2/pan-aldolase (ICT Diagnostics,
South Africa, catalogue number ML02). All of the
respective RDTs were from the same lot, with expiry
date July 2010 (CareStart) or January 2011 (ParaScreen
and ICT Combo). CareStart RDTs are individually pack-
aged with swab, lancet, capillary tube, and buffer. Para-
Screen cassettes and sample loop are individually
packaged, with a single buffer bottle per box. ICT
Combo cassettes are individually wrapped but buffer
and all other components are provided separately in the
box.
Health centre quantitative assessment
Procedures were developed in accordance with Stan-
dards for Reporting of Diagnostic Accuracy (STARD)
guidelines [16]. Patients attending the outpatient
department of the three health centres with symptoms
of uncomplicated malaria (axillary temperature > 37.5°
C or report of fever in the previous 48 hours) were
recruited into the study. Patients under six months of
age or with any life-threatening condition were
excluded. RDTs were transported unrefrigerated by air
to Addis Ababa, where they were stored at ambient
conditions until transfer to field sites. Temperature
was monitored (Tinytag, Gemini Data Loggers, UK)
but not controlled while RDTs were transported by
road to health centres and during storage at the health
centres. Temperatures during transport reached a max-
imum 36°C, but at health facilities temperatures did
n o te x c e e d3 0 ° C .
Sample size was calculated to compare performance of
each RDT to microscopy in detecting both P. falciparum
and P. vivax at each site, assuming RDT sensitivity of
≥ 95% and specificity of ≥ 80%, with 80% power and a 5%
significance level [17]. Assuming > 15% of febrile patients
have microscopy-confirmed malaria infection, at an esti-
mated 60:40 proportion of P. falciparum to P. vivax,a
total of 811 febrile patients were estimated to be needed
at each of the three sites.
Basic demographic information and clinical details
were recorded from each enrolled patient. A single
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nurse, and used to prepare two slides, each with one
thick and one thin film. The same finger prick blood
sample was used to carry out all three RDTs in parallel,
following manufacturer’s instructions. Thin blood films
were fixed in methanol after air-drying, then slides were
stained in 10% Giemsa solution for 15 minutes. Thick
films were read at the health centre by a laboratory
technician and considered negative if no parasites were
seen after examination of 200 fields at ×1,000 magnifica-
tion. When positive for parasites, the number of asexual
parasites per 200 white blood cells, or 500 white blood
cells for low density infections, were used to calculate
the number of asexual parasites per μl of blood, assum-
ing a standard count of 8,000 white blood cells per μlo f
blood [18]. Species, number of parasites/μl (p/μl) and
presence of gametocytes were recorded. RDT and
microscopy results were read by different staff at the
health centre, each blinded to the results of the other
diagnostic technique.
All blood films were re-read a second time by an
experienced microscopist at a regional malaria reference
laboratory, blinded to initial microscopy and RDT
results. A third, blinded, reading was conducted on all
slides with discrepant first and second readings: pre-
sence/absence of asexual parasites, difference in species,
or > 50% difference in parasite count. Microscopy
results and parasite counts were corrected according to
the third reading.
Health post ease of use assessment
Each health post was staffed by two female HEWs or
nurses, who received basic training on the use and inter-
pretation of multi-species RDTs. Each carried out 50
tests with each RDT product during their normal duties
both at the health post and during community outreach
visits. RDTs were discarded after use. Any patient with
suspected malaria was included in the sample.
Interviews were conducted with HEWs after comple-
tion of each set of 50 RDTs. Respondents were asked to
Figure 1 Location of Oromia Regional State (solid shading) and Jimma zone (vertical shading) within Ethiopia. Detail of Jimma zone
indicates study health centres (filled squares) and health posts (filled circles).
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packaging, blood collection device, buffer and results
interpretation (Additional file 2), followed by open-
ended questions to probe for any further preferences.
The various aspects of each RDT were graded on a scale
of one (difficult) to five (very easy). After completion of
all three RDT products, a final interview round was con-
ducted to assess comparative preferences.
Heat stability assessment
Heat stability assessments were conducted between
August and December 2009 at the Ethiopian Health and
Nutrition Research Institute located in Addis Ababa,
designated as a regional reference laboratory by the
World Health Organization (WHO) and the Foundation
for Innovative New Diagnostics (FIND).
Heat stability and lot testing of RDTs was conducted
according to the standard protocol developed by WHO/
FIND [19,20]. RDTs were exposed to 35°C and 45°C for
up to 90 days and to 60°C for up to 72 hours. At pre-
determined periods, RDTs were removed from incuba-
tors and allowed to reach room temperature, then HRP2
and pLDH or aldolase bands were assessed individually
with a negative control and using cultured P. falciparum
and P. vivax at concentrations of 200 and 2,000 p/μl.
For the low parasite density infection, two of each RDT
were tested because of the expected lowered sensitivity,
w h i l eo n l yo n eo fe a c hR D Tw a st e s t e da te a c ht i m e
point with high parasite density samples.
Statistical analysis
Health centre data were entered and verified using
Microsoft® Access 2007 (Microsoft Corporation, Seattle).
Second and third blood film microscopy results were
entered into a Microsoft® Excel 2007 spreadsheet
(Microsoft Corporation, Seattle). All data were analyzed
using STATA version 8.0 (STATA Corporation, College
Station, TX, USA). RDT performance was assessed in
three categories: negative, non-falciparum mono-infec-
tion, and either mixed infection with P. falciparum and
a non-falciparum species, or P. falciparum mono-infec-
tion. The sensitivity, specificity, negative predictive value
(NPV) and positive predictive value (PPV) were calcu-
lated with 95% confidence intervals (CI) for each RDT
[21]. An RDT was categorized as a true positive for P.
vivax infection if only the pan band showed, while an
RDT was categorized as a true negative if the test itself
did not show either of the two test bands and if the cor-
responding blood slide was found to be negative for all
Plasmodium spp. by microscopy. Similarly, an RDT was
categorized as a true positive for P. falciparum or mixed
infection if it showed either the HRP2 and pan band, or
HRP2 band only, while it was considered as a true nega-
tive if it showed no test bands and if no Plasmodium
spp. infection was diagnosed by examination of the cor-
responding blood slide using microscopy. The Kappa
coefficient (), representing the proportion of agree-
ments beyond chance, was used to quantify the level of
agreement between each RDT and ‘gold standard’
microscopy;  ≥ 0.8 was considered to indicate high
reliability [22]. No adjustments were made for multiple
comparison testing. Each of these performance indica-
tors were compared between two RDTs using McNe-
mar’s test [23] to account for the paired nature of
results.
For each of the eleven specific features of the RDTs
graded by HEWs the mean score was calculated and
each test received an overall rating: RDTs were ranked
according to their combined score. All responses to
open-ended questions given during interviews were read
and coded according to common features.
Ethical considerations
The study protocol was approved by the institutional
review boards of the London School of Hygiene and
Tropical Medicine (Application No. 5444) and the
Ethiopian Science and Technology Agency. Patients (or
guardians of children ≤ 16 years) recruited at health
centres provided written informed consent prior to
inclusion. Study participants with microscopy-confirmed
malaria infection were treated according to national
guidelines [24]. At health posts, patients provided verbal
consent before testing with a multi-species RDT was
conducted in addition to routine ParaCheck use.
Results
Study population description
A total of 2,400 febrile patients were enrolled into the
study between May 1 and July 31 2009, 800 at each of
the three health centres. Data from 17 individuals were
excluded due to missing RDT results or unreadable
blood films, therefore full data are available from 2,383
individuals.
Microscopy results
Five hundred and fifty two (23.2%) patients were diag-
nosed with malaria by microscopy, of which (297) 53.8%
and (246) 44.6% were infected with P. falciparum and P.
vivax respectively. Nine (1.6%) confirmed cases had
mixed infection of P. falciparum and P. vivax (Figure 2).
Eight individuals had gametocytes (seven P. falciparum,
one P. vivax) but no asexual parasites. All 2,383 blood
slides were read twice. A total of 496 slides were read a
third time to address discrepancies following the first
and second microscopy readings (Figure 3).
One third (38.4%) of P. falciparum cases had parasite
densities > 5,000 p/μla n do n e - f i f t h( 2 0 . 6 % )<2 0 0p / μl.
About half (52.6%) of patients with P. vivax had parasite
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infection (< 200 p/μl). The geometric mean (95% CI)
parasite count was 1,681 p/μl (1315-2148) for P. falci-
parum and 3,406 p/μl (2844-4080) for P. vivax.
RDT compared to ‘gold standard’ microscopy
RDT results had moderate agreement with microscopy
in detecting P. falciparum or mixed infection ( range
0.6910 to 0.6976) and moderate to good agreement with
microscopy for detection of non-falciparum malaria (
range 0.7531 to 0.8020) (Table 1).
For some Plasmodium-infected patients the RDT
result was positive but the species was incorrectly iden-
tified. The most common species misdiagnosis was
where the RDT showed only the Pan band for P. falci-
parum mono-infections (26 CareStart, 27 ParaScreen
and 25 ICT Combo). Only two of these infections were
> 200 p/μl; with 12,800 p/μla n d4 8 , 0 0 0p / μl. Addition-
ally, RDTs occasionally indicated P. falciparum mono-
infection for what was diagnosed by microscopy to be P.
vivax mono-infection (three CareStart, two ParaScreen
and two ICT Combo). Interestingly, all nine mixed
infections resulted in HRP2 and pan band activation in
CareStart and ICT Combo, while the ParaScreen pan
band failed to show in one of the nine mixed infections.
The sensitivity of all RDTs in detecting P. falciparum
infections was 85.6%. Specificity was statistically similar
for all three RDTs at 92.4% to 92.7% (Table 1). The
PPVs for the RDTs were comparable in detecting P. fal-
ciparum infection at around 65%. NPVs were the same
for all RDTs at 97.5%. The false negative RDT results
for P. falciparum had parasite density between 40 and
50,000 p/μl, with median density 80 p/μl. Species mis-
diagnoses were not considered as false negative results.
CareStart was the best performing RDT in detecting
non-falciparum infections based on kappa ( = 0.8020)
(Table 1), with both CareStart and ICT Combo showing
superior kappa values to that of ParaScreen (p < 0.001
a n dp=0 . 0 3 ,r e s p e c t i v e l y ) .T h eP P Va n dN P Vo fa l l
t h r e eR D T sw e r ec o m p a r a b l e( p>0 . 0 5f o ra l lp a i r s ) ,
however specificity of CareStart was significantly higher
than that of ParaScreen and ICT Combo (p < 0.001 and
p = 0.05, respectively). False negative RDT results
against P. vivax were generally low density infections:
r a n g e4 0t o7 0 8 0p / μlw i t hm e d i a n2 8 0p / μl. Few of the
false positive RDT results for P. vivax or P. falciparum
were due to residual antigen from cleared infections,
since only 11% of patients with false positive results had
received anti-malaria treatment in the previous four
weeks.
Figure 2 Flowchart of microscopy and RDT results.
Ashton et al. Malaria Journal 2010, 9:297
http://www.malariajournal.com/content/9/1/297
Page 5 of 11Sensitivity was calculated for P. falciparum infection
and for P. vivax mono-infection at different parasite den-
sities (< 200 p/μl of blood; 200-500 p/μl; 500-5,000 p/μl;
> 5,000 p/μl) (Table 2). All three RDTs showed improved
sensitivity with increasing P. falciparum density (p <
0.001), but sensitivity was generally comparable between
RDTs within each parasite density category. No statistical
association was seen between P. vivax density and RDT
sensitivity, likely due to the small number of low density
infections. However, CareStart and ICT Combo were
seen to be more sensitive than ParaScreen in detection of
P. vivax infection at > 5000 p/μl (p = 0.03).
Ease of use assessment
All HEWs involved in the ease of use assessment had
previously used ParaCheck, and commented on the
importance of using a multi-species RDT in their work
at the health post and in the community. “This kind of
multi-species RDT is important for our routine activities
and should be immediately applied in our work.”
When all scored components were averaged, CareStart
scored highest (4.5) followed by ParaScreen (4.4) and
ICT Como (4.2). A number of HEWs indicated that they
preferred the packaging of CareStart in individual ‘lab in
ap a c k ’ sets with all components needed for a single test
(cassette, swab, lancet, blood collection pipette, buffer,
and instructions) included in each packet: “I liked having
all materials within a single packet, it makes moving from
house-to-house easier as I don’t have to carry a large box,
so is very comfortable for my work in the community.”
The most salient factor influencing the ease of use of
each RDT was the presence of clear markings on the
cassette for interpretation of results. ParaScreen had the
most detailed labelling with the band positions marked
with ‘C’ at the control region, then ‘Pan’ and ‘Pf’ in the
test region. CareStart has ‘C’ at the control band, with
‘1’ for P. falciparum and ‘2’ for Pan. ICT Combo has no
separate markings for Pf and Pan bands, meaning that
users must remember the band location when reading
results.
Figure 3 Flowchart of microscopy results discrepant between first and second readings.
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Page 6 of 11Table 1 Comparative performance indicators of each RDT
CareStart ParaScreen ICT Combo McNemar p value
1
P. falciparum
2 n = 2137 n = 2137 n = 2137 CS-PS CS-ICT ICT-PS
Sensitivity (95% CI
3) 85.6%
(81.2-89.4)
85.6%
(81.2-89.4)
85.6%
(81.2-89.4)
1.0 1.0 1.0
Specificity (95% CI) 92.4%
(91.1-93.6)
92.4%
(91.1-93.6)
92.7%
(91.4-93.8)
1.0 0.10 0.10
PPV (95% CI) 65.3%
(60.5-70.0)
65.3%
(60.5-70.0)
66.2%
(61.3-70.8)
1.0 0.76 0.76
NPV (95% CI) 97.5%
(96.6-98.2)
97.5%
(96.6-98.2)
97.5%
(96.6-98.2)
1.0 1.0 1.0

4 0.6910 0.6910 0.6976 1.0 0.70 0.70
Non-falciparum only
5 n = 2077 n = 2077 n = 2077 CS-PS CS-ICT ICT-PS
Sensitivity (95% CI) 85.0%
(79.9-89.2)
82.5%
(77.2-87.1)
85.0%
(79.9-89.2)
0.11 1.0 0.08
Specificity (95% CI) 97.2%
(96.4-97.9)
96.2%
(95.3-97.1)
96.7%
(95.8-97.5)
< 0.001 0.05 0.11
PPV (95% CI) 80.4%
(75.0-85.0)
74.7%
(69.0-79.7)
77.7%
(72.2-82.6)
0.10 0.39 0.43
NPV (95% CI) 98.0%
(97.2-98.6)
97.6%
(96.8-98.3)
98.0%
(97.2-98.6)
0.78 1.0 0.50
 0.8020 0.7531 0.7851 < 0.001 0.23 0.03
1 Significant relationships (p > 0.05) in bold type.
2 Individuals with P. falciparum mono-infection or mixed infection with P. falciparum and P. vivax. P. vivax mono-infection excluded.
3 95% Confidence interval.
4 Kappa () is the proportion agreement between microscopy and RDT results, where 0.8 indicates good agreement.
5 Individuals with P. vivax mono-infection. Mixed infections and P. falciparum mono-infection excluded.
Table 2 Sensitivities of RDTs at different parasite densities
CareStart ParaScreen ICT Combo McNemar p value
1
P. falciparum
Parasite density N Sensitivity: Pf or Pf+pan
2 (95% CI
3) CS-PS CS-ICT ICT-PS
< 200 p/μl 63 66.7%
(53.7-78.1)
66.7%
(53.7-78.1)
66.7%
(53.7-78.1)
1.0 1.0 1.0
< 500 p/μl 90 70.0%
(59.4-79.2)
70.0%
(59.4-79.2)
70.0%
(59.4-79.2)
1.0 1.0 1.0
< 5000 p/μl 188 79.1%
(72.6-84.7)
79.1%
(72.6-84.7)
79.1%
(72.6-84.7)
1.0 1.0 1.0
> 5000 p/μl 118 95.8%
(90.4-98.6)
95.7%
(90.4-98.6)
95.7%
(90.4-98.6)
1.0 1.0 1.0
P. vivax
Parasite density N Sensitivity: pan band only
4 (95% CI) CS-PS CS-ICT ICT-PS
< 200 p/μl 9 77.8%
(40.0-97.2)
88.9%
(51.8-99.7)
66.7%
(29.9-92.5)
0.32 0.56 0.16
< 500 p/μl 28 82.1%
(63.1-93.9)
89.3%
(71.8-97.7)
85.7%
(67.3-96.0)
0.32 0.65 0.56
< 5000 p/μl 116 82.8%
(74.6-89.1)
82.8%
(74.6-89.1)
82.8%
(74.6-89.1)
1.0 1.0 1.0
> 5000 p/μl 128 86.7%
(79.6-92.1)
82.8%
(75.1-88.9)
86.7%
(79.6-92.1)
0.03 1.0 0.03
1 Significant relationships (p > 0.05) in bold type.
2 RDT result showed either P. falciparum HRP2 band only, or HRP2 band and pan pLDH band. Individuals with P. vivax infection only excluded.
3 95% Confidence Interval.
4 RDT result showing pan band only. Individuals with any P. falciparum infection excluded.
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CareStart and ParaScreen were shown to have superior
stability to that of ICT Combo during the heat stability
testing. When tested after more than four hours storage
at 60°C, the HRP2 band of ICT Combo failed to detect
infection. The ICT Combo HRP2 band showed only
very weak positive results when tested after 30 days sto-
rage at 35°C and 45°C. However, both CareStart and
ParaScreen HRP2 bands were stable after storage for 72
h o u r sa t6 0 ° C ,a n d9 0d a y sa t3 5 ° Ca n d4 5 ° C ,a l lg i v i n g
positive results when tested with P. falciparum.
All RDTs had pan bands that were more heat-sensitive
than HRP2, appearing faint throughout the testing with
both high and low density P. vivax infections. Both Car-
eStart and ParaScreen pLDH bands completed the test-
ing procedure at 35°C, 45°C and 60°C. The ICT Combo
aldolase band failed to detect P. vivax at 200 p/μla f t e r
60 days stored at 35°C and after 60 days stored at 45°C.
However, after 60 days storage at these temperatures,
ICT Combo did detect P. vivax at the higher density of
2,000 p/μl. ICT Combo aldolase band failed to detect
200 p/μl P. vivax after 72 hours stored at 60°C.
Discussion
RDTs for malaria are being increasingly adopted across
endemic countries to strengthen parasitological diagno-
sis and appropriate management of all fever cases [25].
A large number of products are now available, and
while a detailed assessment of performance has been
undertaken by WHO/FIND [19,20] and a list of recom-
mended products produced [26] it is important that the
most appropriate products for each transmission setting
and operational context are identified. An appropriate
RDT for implementation across Ethiopia should be able
to detect P. falciparum and P. vivax,b eh i g h l ys e n s i t i v e
and specific, and also able to detect low parasite density
infections. PPV and NPV give an indication of useful-
ness of the test in practice, but these indicators are
influenced by the prevalence of malaria in the test popu-
lation. To guide product selection by the FMoH, the
present study set out to determine the performance of
three multi-species RDTs for diagnosis of P. falciparum
and P. vivax malaria in Ethiopia.
The sensitivity of the three RDTs in detecting P. fal-
ciparum was found to be similar to their sensitivity in
detecting P. vivax,a n dt h e r ew a sl i t t l ed i f f e r e n c ei n
RDT performance when compared to microscopy.
Overall, ICT Combo and CareStart showed better per-
formance than ParaScreen. It was unexpected that the
RDTs would have similar sensitivity for detection of
both P. falciparum and P. vivax infection, since other
studies in co-endemic areas have consistently found
multi-species RDTs to be better at detecting P. falci-
parum infection [8,13,27]. The present finding may be
due to misdiagnosis and/or under diagnosis of species
at low parasite density by microscopy. More low den-
sity P. falciparum than P. vivax infections were
detected by microscopy, contrary to findings in other
co-endemic areas where P. falciparum is usually pre-
sents with higher parasite density than P. vivax [9,13].
However, a study in Columbia found similar P. falci-
parum and P. vivax infection densities, but amongst
children under five years the P. vivax parasite density
was higher than P. falciparum [10]. In the present
study all slides were subject to rigorous quality control
testing: read twice by qualified technicians, with any
discrepancies corrected according to an expert micro-
scopist, suggesting that the result is unlikely to be due
to human error.
The maximum recommended storage temperatures for
CareStart and ParaScreen (30°C) was exceeded in the
current study during transport of RDTs to the study
sites (maximum temperature during transit 36°C). This
is unlikely to have contributed to any reduction in per-
formance since heat stability testing indicated that both
CareStart and ParaScreen were able to detect infection
after longer periods being stored at higher temperatures.
Nevertheless, it is important to consider transport and
storage conditions for RDTs during routine use in the
health system.
The RDTs had high NPVs, meaning that they were
reliable in ruling out malaria. However the lower PPV
means that patients will occasionally be falsely diag-
nosed as positive for malaria and unnecessarily treated.
False positives in this study were not due to residual
antigen from previous infections, since only 11% of the
total false positive results were from patients who had
received any anti-malarial treatment in the previous four
weeks. Alternative explanations include sequestration:
erythrocytes containing mature parasites clump together
in the microvasculature, therefore are not seen in the
peripheral circulation and blood films, while antigen
c o n t i n u e st ob er e l e a s e d[ 2 8 ] .I tm a ya l s ob ep o s s i b l e
that the parasite density was too low to be seen by
microscopy, but there was sufficient parasite antigen to
result in a positive RDT [29]. Whilst previous work has
shown that some RDT false positives are due to patients
with residual gametocytaemia [30], this association was
not seen in the current study.
The WHO/FIND product testing of malaria RDTs
[19,20] is the most comprehensive assessment of malaria
RDTs on the market to date. Contrary to the present
results, ParaScreen performed poorly in the WHO/
FIND testing. However CareStart performed slightly bet-
ter in the WHO/FIND testing than in the current study,
as did the HRP2 band of ICT Combo. The aldolase
band of ICT Combo was comparatively better at detect-
ing low density P. vivax in our findings than in the
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sons for this differential performance of the same RDTs
in the two studies. Firstly, the WHO/FIND product test-
ing was carried out by highly experienced technicians in
a controlled laboratory setting, while this study involved
staff engaged in routine activities at the health facility.
Other influencing factors may have been variation
between product lots, the impact of transportation and
storage conditions, or the use of fresh finger-prick blood
samples from patients rather than previously frozen
samples. It is also possible that genetic variation of tar-
get antigens can lead to variation in performance of
RDTs in different regions: Baker et al found significant
genetic variation in HRP2 isolates from different coun-
tries which was associated with reduced sensitivity of
RDTs at low density infections [31]. The prozone effect,
whereby immunological tests are not activated by very
high density infections, has been suggested as a reason
for HRP2 false negative results in malaria RDTs [32].
However in the current study, none of the samples
which elicited false-negative RDT results were hyperpar-
asitaemic (> 5% red blood cells parasitised), therefore
the prozone effect is unlikely to be contributing to the
presence of false negative HRP2 results.
In the Ethiopian context, a number of studies have
been carried out to assess performance of a variety of
multi-species malaria RDTs, to guide the FMOH deci-
sion of a replacement for ParaCheck-Pf. An initial study
found ParaScreen to have much lower sensitivity [27]
than the present study, while a subsequent investigation
during peak transmission season reported comparable
performance [33]. A CareStart pf-HRP2/pv-pLDH com-
bination RDT has also been evaluated at two locations
in Ethiopia [4,5]. The sensitivity of the test in detecting
P. falciparum by HRP2 at Wondo Genet was 99.4% and
96.4% in Jimma, both very much higher than for CareS-
tart pf/pan in the current study. The P. vivax-specific
pLDH band of the pf/pv RDT also appeared to have
much higher sensitivity than the Plasmodium-specific
pLDH band of the pf/pan RDT tested in this study.
Although P. ovale and P. malariae are believed to be
responsible for < 1% of all malaria cases in Ethiopia,
there remains a need to provide parasitological diagnosis
for these species. It is likely that lower performance of
pf/pan RDTs in this study compared to prior pf/pv RDT
findings is a result of conducting the study under opera-
tional conditions. Furthermore, the WHO/FIND evalua-
tion indicates that pf/pan and pf/pv RDTs have
comparable performance [19,20].
CareStart also manufactures a pf-pLDH/pan-pLDH
combination test, which has been evaluated in Madagas-
car [12] and Myanmar [9]. The sensitivity of pan-pLDH
in the current study falls between the values determined
in Madagascar and Myanmar, indicating that our results
for CareStart pan-pLDH are reliable.
Ability of the end-user to correctly prepare and inter-
pret the RDT is crucial to operational success. Ease of
u s eh a sb e e ns h o w nt ov a r yc o n s i d e r a b l yw i t hd i f f e r e n t
RDT formats [34,35] and reduce test accuracy if health
workers do not receive sufficient training or support
tools [36]. WHO acknowledges the importance of
selecting an RDT appropriate to the level of training
and supervision of the end-user [19]. The ‘lab in a pack’
format and clear labelling of the cassette bands were
factors that HEWs valued, supporting adoption of Car-
eStart for use at health posts in Ethiopia, but the current
work did not investigate whether HEW preferences
affect the use of RDT results to make case management
decisions. In order for multi-species RDTs to be fully
effective at health post level, it is necessary to confirm
that results of RDTs are correctly transferred to treat-
ment or referral procedures.
Results of heat stability assessment for CareStart
were consistent between the WHO/FIND testing and
the current study, with strong detection rates after
storage at 35°C and 45°for low and high-density P. fal-
ciparum and P. vivax samples. ParaScreen was found
to perform better in heat stability testing during the
current study than in the WHO/FIND product testing,
where failures occurred with low density P. falciparum
and P. vivax infections. ICT Combo performed well in
WHO/FIND testing, with the HRP2 band detecting all
P. falciparum samples, but in our study ICT Combo
failed to detect one high density P. falciparum sample
and showed weak responses towards the end of the
testing period. Test procedures were the same for
both studies and the discrepancy in ParaScreen results
may therefore be due to variation between product
lots.
Conclusions
All three RDTs showed performance below WHO
recommendations for sensitivity compared to ‘gold stan-
dard microscopy’. Health extension workers were easily
able to adapt to the use of multi-species RDTs after lim-
ited training. For use at health posts, ICT Combo
seemed least suitable, as it did not provide reliable
results after being stored at ambient temperatures. Con-
sidering a combination of reliability compared to micro-
scopy, heat stability, and ease of use judged by health
extension workers, CareStart pf-HRP2/pan-pLDH is
found to be the most appropriate tool to allow for para-
sitological diagnosis at health post level in Ethiopia.
However the selection of RDT should be regularly re-
evaluated as new products are released, to ensure that
the most appropriate test is used.
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